These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 35695606)

  • 1. PD-L1 Overexpression in the Lungs of Subjects Who Died from COVID-19: Are We on the Way to Understanding the Immune System Exhaustion Induced by SARS-CoV-2?
    Ronchi A; Marino FZ; Carraturo E; La Mantia E; Campobasso CP; De Micco F; Mascolo P; Municinò M; Mucininò E; Vestini F; Pinto O; Moccia M; De Stefano N; Nappi O; Sementa C; Zotti G; Pianese L; Giordano C; Fico A; Franco R
    Crit Rev Eukaryot Gene Expr; 2022; 32(3):9-20. PubMed ID: 35695606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Dysregulation in COVID-19 Patients.
    Sabbatino F; Conti V; Franci G; Sellitto C; Manzo V; Pagliano P; De Bellis E; Masullo A; Salzano FA; Caputo A; Peluso I; Zeppa P; Scognamiglio G; Greco G; Zannella C; Ciccarelli M; Cicala C; Vecchione C; Filippelli A; Pepe S
    Front Immunol; 2021; 12():695242. PubMed ID: 34163490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: A Peculiar Case of Inflammatory Colitis After SARS-CoV-2 Infection.
    Rutigliani M; Bozzo M; Barberis A; Greppi M; Anelli E; Castellaro L; Bonsignore A; Azzinnaro A; Pesce S; Filauro M; Rollandi GA; Castagnola P; Candiani S; Marcenaro E
    Front Immunol; 2022; 13():849140. PubMed ID: 35222440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adipose-Tissue-Derived Mesenchymal Stem Cells Mediate PD-L1 Overexpression in the White Adipose Tissue of Obese Individuals, Resulting in T Cell Dysfunction.
    Eljaafari A; Pestel J; Le Magueresse-Battistoni B; Chanon S; Watson J; Robert M; Disse E; Vidal H
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity.
    Beserra DR; Alberca RW; Branco ACCC; de Mendonça Oliveira L; de Souza Andrade MM; Gozzi-Silva SC; Teixeira FME; Yendo TM; da Silva Duarte AJ; Sato MN
    J Immunol Res; 2022; 2022():9764002. PubMed ID: 35971391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis.
    Aghbash PS; Eslami N; Shamekh A; Entezari-Maleki T; Baghi HB
    Life Sci; 2021 Apr; 270():119124. PubMed ID: 33508291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased PD-L1 Expression May Be Associated With the Cytokine Storm and CD8+ T-Cell Exhaustion in Severe COVID-19.
    Chen J; Vitetta L
    J Infect Dis; 2021 May; 223(9):1659-1660. PubMed ID: 33524110
    [No Abstract]   [Full Text] [Related]  

  • 8. Intermediate Monocytes with PD-L1 and CD62L Expression as a Possible Player in Active SARS-CoV-2 Infection.
    Rutkowska E; Kwiecień I; Kłos K; Rzepecki P; Chciałowski A
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion.
    Huang HC; Wang SH; Fang GC; Chou WC; Liao CC; Sun CP; Jan JT; Ma HH; Ko HY; Ko YA; Chiang MT; Liang JJ; Kuo CT; Lee TA; Morales-Scheihing D; Shen CY; Chen SY; McCullough LD; Cui L; Wernig G; Tao MH; Lin YL; Chang YM; Wang SP; Lai YJ; Li CW
    J Med Virol; 2023 Feb; 95(2):e28478. PubMed ID: 36609964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of RNA In Situ Hybridization and Immunohistochemistry Techniques for the Detection and Localization of SARS-CoV-2 in Human Tissues.
    Massoth LR; Desai N; Szabolcs A; Harris CK; Neyaz A; Crotty R; Chebib I; Rivera MN; Sholl LM; Stone JR; Ting DT; Deshpande V
    Am J Surg Pathol; 2021 Jan; 45(1):14-24. PubMed ID: 32826529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness.
    Morrell ED; Bhatraju PK; Sathe NA; Lawson J; Mabrey L; Holton SE; Presnell SR; Wiedeman A; Acosta-Vega C; Mitchem MA; Liu T; Chai XY; Sahi S; Brager C; Orlov M; Sakr SS; Sader A; Lum DM; Koetje N; Garay A; Barnes E; Cromer G; Bray MK; Pipavath S; Fink SL; Evans L; Long SA; West TE; Wurfel MM; Mikacenic C
    Am J Physiol Lung Cell Mol Physiol; 2022 Jul; 323(1):L14-L26. PubMed ID: 35608267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung.
    Goldmann T; Marwitz S; Nitschkowski D; Krupar R; Backman M; Elfving H; Thurfjell V; Lindberg A; Brunnström H; La Fleur L; Mezheyeuski A; Mattsson JSM; Botling J; Micke P; Strell C
    Cancer Immunol Immunother; 2021 Sep; 70(9):2577-2587. PubMed ID: 33576873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the PD-1 and PD-L1 axis in COVID-19.
    R Bonam S; Hu H; Bayry J
    Future Microbiol; 2022 Sep; 17():985-988. PubMed ID: 35899493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased PD-L1 surface expression on peripheral blood granulocytes and monocytes after vaccination with SARS-CoV2 mRNA or vector vaccine.
    Loacker L; Kimpel J; Bánki Z; Schmidt CQ; Griesmacher A; Anliker M
    Clin Chem Lab Med; 2023 Jan; 61(1):e17-e19. PubMed ID: 36245120
    [No Abstract]   [Full Text] [Related]  

  • 15. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
    Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of In Situ Hybridization, Immunohistochemistry, and Reverse Transcription-Droplet Digital Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing in Tissue.
    Roden AC; Vrana JA; Koepplin JW; Hudson AE; Norgan AP; Jenkinson G; Yamaoka S; Ebihara H; Monroe R; Szabolcs MJ; Majumdar R; Moyer AM; García JJ; Kipp BR
    Arch Pathol Lab Med; 2021 Jul; 145(7):785-796. PubMed ID: 33720333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension.
    Zeng Q; Li YZ; Dong SY; Chen ZT; Gao XY; Zhang H; Huang G; Xu Y
    Front Immunol; 2020; 11():596684. PubMed ID: 33362779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Induces Cytokine Responses in Human Basophils.
    Bonam SR; Chauvin C; Levillayer L; Mathew MJ; Sakuntabhai A; Bayry J
    Front Immunol; 2022; 13():838448. PubMed ID: 35280992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D can reduce severity in COVID-19 through regulation of PD-L1.
    Aygun H
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Apr; 395(4):487-494. PubMed ID: 35099571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.